Lilly needs a plan to spur weight-loss drug sales, investors say
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...
Yahoo Finance7d
Zepbound sales keep soaring, even as weight loss drug growth slows
Sales of Eli Lilly’s (LLY) blockbuster weight-loss ... Zepbound sales reached $1.9 billion in the fourth quarter of 2024, compared with $176 million during the same period in 2023 — when it ...
WVU Medicine leads trial of procedure to maintain weight loss without GLP-1 drugs
WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for people who've ...
Will This New GLP-1 Drug be More Powerful Than Ozempic?
CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.
AOL8d
Prescriptions for weight loss drugs are skyrocketing, especially among young women. Experts think they know why.
Starting in 2022, Haley Sipes lost 75 pounds over 10 months with diet and exercise alone. On TikTok, where the 31-year-old mother of three chronicled her weight loss journey, commenters speculated ...
AOL11d
With Zepbound Not Matching Expectations, Should Investors Give Up on Eli Lilly?
Over the past six months, Eli Lilly (NYSE ... giant is one of the undisputed leaders in the exciting market for weight loss drugs. It turns out that the anti-obesity space isn't growing as ...
Yahoo Finance8d
Lilly needs a plan to spur weight-loss drug sales, investors say
(Reuters) - Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales of popular weight-loss drug Zepbound after it last month ...